Profitability
Weight: 25%
C+
61
- 5yr Avg ROIC 18.2%
- Operating Margin Trend -6.40 pp/yr
CORT
Corcept Therapeutics Incorporated
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
Capital Efficiency
Weight: 15%
A-
84
- 5yr Avg ROE 17.3%
- 5yr Share-Count CAGR -1.2%
Growth Quality
Weight: 25%
B
71
- 5yr Revenue CAGR 20.1%
- 5yr EPS CAGR -2.0%
- Revenue-Growth Years (5) 5/5
Cash Generation
Weight: 20%
A+
97
- 5yr FCF Margin 29.9%
- 5yr FCF/NI Conversion 1.34x
Balance Sheet
Weight: 10%
A+
100
- Net Debt / EBITDA -5.36x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score 31.55
Stability
Weight: 5%
B-
62
- EPS Volatility (σ/μ) 0.38
- Piotroski F-Score 5
- Negative-Revenue Years (5) 0/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.4 of 4 gurus held; 1 new buy; 2 added; 1 trimmed.
- Holders
- 4 +1
- Avg Δ position
- +171.1%
- New buys
- 1
- Full exits
- 0